Alliance Shift: Private Biotechs See Up-Front Cash Boost In 2012
This article was originally published in Start Up
Biopharma alliance volume has dropped over the past five years, but in 2012, privately held out-licensers averaged better up-fronts than their publicly traded counterparts, according to Elsevier’s Strategic Transactions.
You may also be interested in...
Armed with cash from a robust M&A and a stock market boom, mutual and hedge funds are eagerly crossing over into mezzanine rounds for private biotechs and playing key roles in some of the year’s biggest venture financings.
Rather than partner its implantable formulation of exenatide, the biotech turned to hedge funds and other non-traditional investors for the year’s largest round of private capital. The deal enables Intarcia to begin Phase III trials on lead program ITCA-650 for type 2 diabetes, which it believes could be a blockbuster.
Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.